Article citationsMore>>

Wagner, K.D., Redden, L., Kowatch, R.A., Wilens, T.E., Segal, S., Chang, K., Wozniak, P., Vigna, N.V., Abi-Saab, W. and Saltarelli, M. (2009) A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 519-532. doi:10.1097/CHI.0b013e31819c55ec

has been cited by the following article:

• TITLE: An open-label trial of divalproex sodium extended release for pediatric bipolar spectrum disorder in children age 6 - 12 years

  AUTHORS: Janet Wozniak, Paul Hammerness, Robert Doyle, Gagan Joshi, K. Yvonne Woodworth, Joseph Biederman

  KEYWORDS: Bipolar Disorders; Pediatric; Psychopharmacology; Open-Label

  JOURNAL NAME: Open Journal of Psychiatry, Vol.2 No.2, April 18, 2012

  ABSTRACT: Objective: To estimate the rate of response to divalproex sodium extended release in pediatric bipolar spectrum disorder in young children age 6 - 12. Methods: This was an 8-week, open-label treatment of youth with DSM-IV bipolar disorder with divalproex sodium extended release (ER) monotherapy. Severity of mania was assessed weekly with the Young Mania Rating Scale (YMRS). Results: The sample was 8.9 ± 2.0 years of age and predominantly male (83%). At study entry the mean YMRS score was 26.3 ± 4.5. Of the 18 subjects enrolled, 7 (39%) completed the 8 week course. We failed to find a clinically or statistically significant improvement with divalproex sodium ER. Pre-post comparisons at endpoint (LOCF) indicated an average response reduction of 6.1 ± 2.6 in the YMRS to a mean of 20.3 ± 8.1. Weight increased by 1.36 ± 0.7 kg (p = 0.08) from baseline to endpoint. Conclusion. Divalproex sodium ER monotherapy was associated with poor tolerability, was associated with clinically concerning weight gain but had modest therapeutic benefits in the management of symptoms of mania and depression in children with pediatric bipolar disorder.